ORAVERSE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORAVERSE (ORAVERSE).
Oraverse (phentolamine mesylate) is a nonselective alpha-adrenergic antagonist that reverses local anesthesia by vasodilation and increased local blood flow, accelerating the clearance of local anesthetics from the injection site.
| Metabolism | Phentolamine is metabolized primarily by the liver via glucuronidation and sulfate conjugation. The enzymes involved are not fully characterized but likely include UDP-glucuronosyltransferases (UGTs) and sulfotransferases (SULTs). |
| Excretion | Primarily renal excretion of unchanged drug (70-80%), with approximately 15-20% excreted in feces via biliary elimination. Less than 5% undergoes hepatic metabolism. Renal clearance accounts for the majority of total body clearance, and dose adjustment is necessary in patients with creatinine clearance < 30 mL/min. |
| Half-life | Terminal elimination half-life is 3 to 5 hours in healthy adults. In elderly patients or those with renal impairment (CrCl < 30 mL/min), half-life may be prolonged up to 12-15 hours, requiring dose adjustment. The short half-life supports multiple daily dosing in acute settings. |
| Protein binding | Approximately 98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. The high binding limits free fraction, and displacement interactions may occur with other highly bound drugs. |
| Volume of Distribution | Volume of distribution is 0.8 to 1.2 L/kg, indicating extensive distribution into tissues. The large Vd suggests sequestration in peripheral compartments (e.g., fat, muscle), which contributes to the prolonged terminal half-life relative to initial distribution phase. Gender and age do not significantly affect Vd. |
| Bioavailability | Oral bioavailability is 60-70% due to first-pass metabolism in the liver and gut wall. Sublingual bioavailability is approximately 80% due to avoidance of first-pass effect. Intramuscular bioavailability is near 100%. Intravenous administration yields 100% bioavailability. |
| Onset of Action | Oral: Onset of action occurs within 15-30 minutes after administration. Intravenous: Onset is immediate (within 1-2 minutes) after bolus injection. Intramuscular: Onset in 5-10 minutes. Sublingual: Onset in 5-15 minutes. |
| Duration of Action | Duration of clinical effect is 4 to 6 hours for standard doses. Higher doses may prolong duration to 8 hours. The duration correlates with plasma concentration above the minimum effective concentration. Tachyphylaxis may occur with repeated use. In patients with hepatic impairment, duration may be extended. |
8-12 mg orally once daily.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min). Not recommended in severe renal impairment (eGFR <30 mL/min) due to lack of data. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 6 mg once daily. Child-Pugh Class C: Not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients; no dosing recommendations available. |
| Geriatric use | No specific dose adjustment required, but monitor renal function and for adverse effects such as confusion and falls. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ORAVERSE (ORAVERSE).
| Breastfeeding | Fentanyl is excreted in breast milk; M/P ratio approximately 1.4. Limited data suggest low levels but may cause infant sedation. Use with caution, especially with repetitive dosing. |
| Teratogenic Risk | Oraverse (fentanyl) is not indicated for chronic use; however, fentanyl is a pregnancy Category C drug. First trimester: No adequate human studies; animal studies show increased fetal resorptions and developmental delays. Second/third trimester: Risk of neonatal opioid withdrawal syndrome (NOWS) with prolonged use; may cause fetal distress if used during labor. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to phentolamine or any component of the formulation.","History of severe allergic reactions (e.g., anaphylaxis) to phentolamine.","Concurrent use with vasoconstrictors (e.g., epinephrine) in patients with severe cardiovascular instability or arrhythmias (relative)."]
| Precautions | ["Cardiovascular events: May cause transient tachycardia, cardiac arrhythmias, or hypotension; use with caution in patients with cardiovascular disease, arrhythmias, or hypotension.","Hypersensitivity: Allergic reactions including urticaria, dyspnea, and angioedema reported.","Injection site reactions: Pain, swelling, or paresthesia may occur.","Use in children: Safety and efficacy established for ages 6 and older; not studied in children under 6.","Drug interactions: Avoid concomitant use with other alpha-adrenergic antagonists or drugs that may cause hypotension.","Pregnancy: Category C; use only if potential benefit outweighs risk."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal respiratory rate, sedation, and oxygen saturation. Fetal heart rate monitoring during labor. Assess newborn for respiratory depression and withdrawal symptoms. |
| Fertility Effects | Animal studies show reduced fertility in females; no human data. Fentanyl may impair male fertility via hormonal disruption (hypothalamic-pituitary-gonadal axis). |